Propylthiouracil-Associated Antineutrophil Cytoplasmic Antibodies Resulted Microscopic Polyangiitis and Pulmonary-Renal Syndrome A Case Report and Literature Review

Propylthiouracil (PTU) is a thionamide used for hyperthyroidism. Numbers of PTU induced adverse reactions such as leukopenia, rash, fever, arthritis, vasculitis, and lupus-like syndrome are reported. In addition, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis during PTU therapy was reported. Pulmonary-renal syndrome is one infrequent but life-threatening presentation of PTU-associated ANCA-positive vasculitis. We report a 45-year-old woman with pulmonary-renal syndrome presented as hemoptysis, normocytic anemia, and microscopic hematuria during the treatment of Graves' disease with PTU. Her serum perinuclear-ANCA was positive and dysmorphic red blood cells were found in urinalysis. After discontinuing PTU and starting immunosuppressive agent treatment, the fever, hematuria, and pulmonary hemorrhage subsided but the p-ANCA was still present several months later. ANCA-associated pulmonary-renal syndrome may be a complication of PTU therapy. The proportion of ANCA-positive case increases with the prolongation of PTU therapy. In contrast, there are rare reports of ANCA-associated vasculitis in the other thionamide i.e. carbimazole and methimazole. Therefore, carbimazole or methimazole may be the drug of choice when long-term treatment for hyperthyroidism is required.

[1]  J. Franklyn,et al.  Propylthiouracil and carbimazole associated‐antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves’ disease , 2004, Clinical endocrinology.

[2]  Chien-Ning Huang,et al.  Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan. , 2004, Journal of the Formosan Medical Association = Taiwan yi zhi.

[3]  M. Tsai,et al.  Methimazole-induced pulmonary hemorrhage associated with antimyeloperoxidase-antineutrophil cytoplasmic antibody: a case report. , 2001, Journal of the Formosan Medical Association = Taiwan yi zhi.

[4]  P. Merkel,et al.  Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. , 2000, Arthritis & Rheumatism.

[5]  P. Cockwell,et al.  Case of propylthiouracil-induced ANCA associated small vessel vasculitis. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  R. Falk,et al.  Small-vessel vasculitis. , 1997, The New England journal of medicine.

[7]  H. Schuppe,et al.  T cells ignore the parent drug propylthiouracil but are sensitized to a reactive metabolite generated in vivo. , 1996, Clinical immunology and immunopathology.

[8]  M. J. Hurst,et al.  Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. , 1995, British journal of rheumatology.

[9]  R. Bernstein,et al.  Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis. , 1994, British journal of rheumatology.

[10]  R. Goldschmeding,et al.  Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy , 1993, The Lancet.

[11]  S. Stankus,et al.  Propylthiouracil-induced hypersensitivity vasculitis presenting as respiratory failure. , 1992, Chest.

[12]  J. Uetrecht,et al.  Oxidation of propylthiouracil to reactive metabolites by activated neutrophils. Implications for agranulocytosis. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[13]  E. Lee,et al.  Mechanism of inactivation of myeloperoxidase by propylthiouracil. , 1990, Biochemical pharmacology.

[14]  S. Hara,et al.  Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis associated with thiamazole therapy. , 1996, Nephron.